To preliminarily determine the appropriate dosage of carboplatin （CBP） at AUC of 5 mg-M1^-1·min^-1 in the combination chemotherapy for Chinese senile patients with non-small cell lung cancer （NSCLC）. Thirty-f...To preliminarily determine the appropriate dosage of carboplatin （CBP） at AUC of 5 mg-M1^-1·min^-1 in the combination chemotherapy for Chinese senile patients with non-small cell lung cancer （NSCLC）. Thirty-five Chinese senile patients with NSCLC in advanced stage （Ⅲ/Ⅳ） were given 96 cycles of combination chemotherapy. Chemotherapy schedules included Taxol＋CBP, Gemzar＋CBP and NVB＋CBE The dose of CBP was at 5 mg.mL^-1·min^-1 of area under the concentration-time curve （AUC）. Side effects and quality of life were observed before and after the chemotherapy. Myelosuppression was severe and commonly observed. Grade 3/4 of granulocytopenia was found in 47.9% （46/96） of the patients and grade 3/4 of thrombocytopenia was noted in 28.1% （27/96） of the subjects. However, other side effects were slight. The mean score of quality of life （QOL）, according to the criteria of QOL for Chinese cancer patients had reduced 6.8. At 5 mg.mL^-1·min^-1 by AUC, the hematological toxicity of CBP was severe and it had some negative effects on the QOL. The administration of CBP at 5 mg.mL^-1·min^-1 by AUC may be too high for Chinese senile patients with non-small cell lung cancer.展开更多
Since 1984, mass screening for cancer and chemopreventive trials in the two high incidence areas of lung cancer have been carried out. Chemo preventive trials on the subjects having moderate or severe atypical hyperpl...Since 1984, mass screening for cancer and chemopreventive trials in the two high incidence areas of lung cancer have been carried out. Chemo preventive trials on the subjects having moderate or severe atypical hyperplasia cells in the sputum were done by treatment with R1 [N-(p-ethoxycarbophenyl) retinamide] and R2 [N-(p-carboxyphenyl) retina-mide]. Results showed that the general status of the patients had improved. IgA and IgM in the serum were increased and the arsenic skin lesions were relieved after the treatment with Rl and R2. The ratio of the incidence of lung cancer for the treated group and the control group was 1:4, and the mean degree of hyperplasia in the sputum had dropped. It is suggested that these drugs are both safe and effective in the chemoprevention of lung cancer.展开更多
目的:分析腧穴揿针疗法治疗青海地区慢性阻塞性肺疾病加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)(痰浊阻肺证)患者的临床价值。方法:选取2019年7月~2020年7月于我院收治的83例AECOPD(痰浊阻肺证)患...目的:分析腧穴揿针疗法治疗青海地区慢性阻塞性肺疾病加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)(痰浊阻肺证)患者的临床价值。方法:选取2019年7月~2020年7月于我院收治的83例AECOPD(痰浊阻肺证)患者的临床资料,根据不同治疗方法分研究组(n=43,予以腧穴揿针疗法治疗)和对照组(n=40,常规治疗)。对比两组患者临床疗效、炎性因子[白介素6(interleukin-6,IL-6)、肿瘤坏死因子-α(Tumor necrosis factorα,TNF-α)水平、C反应蛋白(C-reaction protein,CRP)]、中医证候、慢性阻塞性肺病评估测试(COPDAssessment TestTM,CAT)评分、呼吸困难指数[改良英国MRC呼吸困难指数(modified british medical research council,mMRC)]、不良反应。结果:研究组患者总有效率(93.02%)vs明显高于对照组(75.00%)(P<0.05);治疗后两组IL-6、CRP及TNF-α均较治疗前降低,但研究组炎性因子水平在治疗后明显低于对照组(P<0.05);两组患者治疗后中医证候评分及CAT评分均较治疗前降低,研究组明显较对照组低(P<0.05);治疗前,两组mMRC量表评分处于3、4级患者居多(P>0.05),治疗后,两组mMRC量表评分以0~2级者占多数,且研究组处于0~2级患者显著高于对照组(P<0.05);两组治疗期间均未出现严重不良反应。结论:对青海地区AECOPD(痰浊阻肺证)患者予以腧穴揿针疗法治疗临床疗效佳,可显著抑制炎性因子,改善患者呼吸困难及肺部情况,值得临床推广应用。展开更多
基金a grant from a key research program of the Education Bureau of Hubei Province (D2006-02-002).
文摘To preliminarily determine the appropriate dosage of carboplatin （CBP） at AUC of 5 mg-M1^-1·min^-1 in the combination chemotherapy for Chinese senile patients with non-small cell lung cancer （NSCLC）. Thirty-five Chinese senile patients with NSCLC in advanced stage （Ⅲ/Ⅳ） were given 96 cycles of combination chemotherapy. Chemotherapy schedules included Taxol＋CBP, Gemzar＋CBP and NVB＋CBE The dose of CBP was at 5 mg.mL^-1·min^-1 of area under the concentration-time curve （AUC）. Side effects and quality of life were observed before and after the chemotherapy. Myelosuppression was severe and commonly observed. Grade 3/4 of granulocytopenia was found in 47.9% （46/96） of the patients and grade 3/4 of thrombocytopenia was noted in 28.1% （27/96） of the subjects. However, other side effects were slight. The mean score of quality of life （QOL）, according to the criteria of QOL for Chinese cancer patients had reduced 6.8. At 5 mg.mL^-1·min^-1 by AUC, the hematological toxicity of CBP was severe and it had some negative effects on the QOL. The administration of CBP at 5 mg.mL^-1·min^-1 by AUC may be too high for Chinese senile patients with non-small cell lung cancer.
文摘Since 1984, mass screening for cancer and chemopreventive trials in the two high incidence areas of lung cancer have been carried out. Chemo preventive trials on the subjects having moderate or severe atypical hyperplasia cells in the sputum were done by treatment with R1 [N-(p-ethoxycarbophenyl) retinamide] and R2 [N-(p-carboxyphenyl) retina-mide]. Results showed that the general status of the patients had improved. IgA and IgM in the serum were increased and the arsenic skin lesions were relieved after the treatment with Rl and R2. The ratio of the incidence of lung cancer for the treated group and the control group was 1:4, and the mean degree of hyperplasia in the sputum had dropped. It is suggested that these drugs are both safe and effective in the chemoprevention of lung cancer.
文摘目的:分析腧穴揿针疗法治疗青海地区慢性阻塞性肺疾病加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)(痰浊阻肺证)患者的临床价值。方法:选取2019年7月~2020年7月于我院收治的83例AECOPD(痰浊阻肺证)患者的临床资料,根据不同治疗方法分研究组(n=43,予以腧穴揿针疗法治疗)和对照组(n=40,常规治疗)。对比两组患者临床疗效、炎性因子[白介素6(interleukin-6,IL-6)、肿瘤坏死因子-α(Tumor necrosis factorα,TNF-α)水平、C反应蛋白(C-reaction protein,CRP)]、中医证候、慢性阻塞性肺病评估测试(COPDAssessment TestTM,CAT)评分、呼吸困难指数[改良英国MRC呼吸困难指数(modified british medical research council,mMRC)]、不良反应。结果:研究组患者总有效率(93.02%)vs明显高于对照组(75.00%)(P<0.05);治疗后两组IL-6、CRP及TNF-α均较治疗前降低,但研究组炎性因子水平在治疗后明显低于对照组(P<0.05);两组患者治疗后中医证候评分及CAT评分均较治疗前降低,研究组明显较对照组低(P<0.05);治疗前,两组mMRC量表评分处于3、4级患者居多(P>0.05),治疗后,两组mMRC量表评分以0~2级者占多数,且研究组处于0~2级患者显著高于对照组(P<0.05);两组治疗期间均未出现严重不良反应。结论:对青海地区AECOPD(痰浊阻肺证)患者予以腧穴揿针疗法治疗临床疗效佳,可显著抑制炎性因子,改善患者呼吸困难及肺部情况,值得临床推广应用。
